The histone methyltransferase Wolf–Hirschhorn syndrome candidate 1‐like 1 (WHSC1L1) is involved in human carcinogenesis

67 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

SMYD3-mediated lysine methylation in the PH domain is critical for activation of AKT1 (2016, unknown): “Small interfering RNA (siRNA) oligonucleotide duplexes were purchased from Sigma-Aldrich for targeting the human SMYD3 transcript. siEGFP was used as a control siRNA [47–52].”
Histone Modifications and Cancer. (2016, background): “NSD3 H3K36 Overexpressed in CML, bladder, lung, and liver cancers (Kang et al. 2013); amplified in human”
WHSC1L1 drives cell cycle progression through transcriptional regulation of CDC6 and CDK2 in squamous cell carcinoma of the head and neck (2016, unknown): “Taking the above into consideration, as well as the very low expression levels of WHSC1L1 in normal tissues [19], WHSC1L1 may serve as a promising candidate for drug development for patients with SCCHN as well as other cancer types characterized by WHSC1L1 amplification or overexpression.”
WHSC1L1-mediated EGFR mono-methylation enhances the cytoplasmic and nuclear oncogenic activity of EGFR in head and neck cancer (2017, unknown): “Taking the above into consideration, and that WHSC1L1 has overall low expression levels in normal tissues 28 , this protein lysine methyltransferase may represent an important target for drug development in SCCHN patients with aberrant expression of this enzyme.”